{
    "clinical_study": {
        "@rank": "65669", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of flavopiridol in treating patients with\n      recurrent intermediate-grade or high-grade non-Hodgkin's lymphoma or mantle cell lymphoma.\n      Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they\n      stop growing or die."
        }, 
        "brief_title": "Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma", 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the objective response rate to flavopiridol by patients with previously treated\n      intermediate and high grade non-Hodgkin's lymphoma and mantle cell lymphoma.\n\n      II. Determine the toxicity of flavopiridol administered as a continuous infusion every 2\n      weeks in these patients.\n\n      III. Study the pharmacokinetics of flavopiridol in these patients.\n\n      OUTLINE: This is an open label, multi-institutional study.\n\n      Patients receive treatment on an outpatient basis. Flavopiridol is administered as a\n      continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of\n      therapy unless unacceptable toxicity or disease progression occurs. Patients are followed\n      until death."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma (NHL) and\n             mantle cell lymphoma with clinical or pathological evidence of recurrent disease\n\n          -  Measurable or evaluable disease\n\n          -  CNS metastases not requiring intravenous steroid therapy allowed\n\n        PATIENT CHARACTERISTICS:\n\n          -  Age: 18 and over\n\n          -  Performance status: CALGB 0-2\n\n          -  Life expectancy: At least 12 weeks\n\n          -  Absolute neutrophil count at least 1500/mm3 (unless due to bone marrow involvement by\n             lymphoma)\n\n          -  Platelet count at least 100,000/mm3 (unless due to bone marrow involvement by\n             lymphoma)\n\n          -  At least 7 days since platelet transfusion\n\n          -  Hemoglobin at least 9.0 g/dL\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  Transaminases no greater than 2.5 times upper limit of normal\n\n          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min\n\n          -  No significant uncontrolled medical or psychiatric illness\n\n          -  No active serious infection\n\n          -  Not pregnant or lactating\n\n          -  Fertile patients must use effective contraception\n\n          -  Central venous catheter required prior to study entry\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  No more than 1 prior chemotherapy regimen\n\n          -  At least 4 weeks since prior chemotherapy and recovered from all toxic effects Prior\n             chemotherapy must contain anthracycline if intermediate or high-grade NHL other than\n             mantle cell\n\n          -  No concurrent treatment with other chemotherapeutic or investigational antineoplastic\n             drugs\n\n          -  At least 4 weeks since prior radiation therapy and recovered (Site of only measurable\n             disease must not be located within prior radiation therapy port)\n\n          -  No concurrent radiation therapy to any lesion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003039", 
            "org_study_id": "NCI-2012-02253", 
            "secondary_id": [
                "UCCRC-8548", 
                "NCI-T96-0099", 
                "CDR0000065663"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Arm I", 
            "intervention_name": "alvocidib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Flavopiridol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent grade 3 follicular lymphoma", 
            "recurrent adult diffuse small cleaved cell lymphoma", 
            "recurrent adult diffuse mixed cell lymphoma", 
            "recurrent adult diffuse large cell lymphoma", 
            "recurrent adult immunoblastic large cell lymphoma", 
            "recurrent adult lymphoblastic lymphoma", 
            "recurrent adult Burkitt lymphoma", 
            "recurrent mantle cell lymphoma"
        ], 
        "lastchanged_date": "February 4, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCCRC-8548"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Cancer Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Clinical Sciences Building"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60640"
                    }, 
                    "name": "Louis A. Weiss Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62526"
                    }, 
                    "name": "Cancer Care Specialists of Central Illinois, S.C."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60201"
                    }, 
                    "name": "Evanston Northwestern Health Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Park Ridge", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60068"
                    }, 
                    "name": "Lutheran General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peoria", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61602"
                    }, 
                    "name": "Oncology/Hematology Associates of Central Illinois, P.C."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62701"
                    }, 
                    "name": "Central Illinois Hematology Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Wayne", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46885-5099"
                    }, 
                    "name": "Fort Wayne Medical Oncology and Hematology, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Bend", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46617"
                    }, 
                    "name": "Michiana Hematology/Oncology P.C."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients With Previously Treated Intermediate and High Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma", 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "Todd M. Zimmerman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2000", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 1997", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {
        "Cancer Care Specialists of Central Illinois, S.C.": "39.84 -88.955", 
        "Central Illinois Hematology Oncology Center": "39.782 -89.65", 
        "Clinical Sciences Building": "41.878 -87.63", 
        "Evanston Northwestern Health Care": "42.041 -87.69", 
        "Fort Wayne Medical Oncology and Hematology, Inc.": "41.079 -85.139", 
        "Louis A. Weiss Memorial Hospital": "41.878 -87.63", 
        "Lutheran General Hospital": "42.011 -87.841", 
        "Michiana Hematology/Oncology P.C.": "41.683 -86.25", 
        "Oncology/Hematology Associates of Central Illinois, P.C.": "40.694 -89.589", 
        "University of Chicago Cancer Research Center": "41.878 -87.63"
    }
}